Policy / Pricing SCOTUS won’t hear pharma’s IRA complaints PharmaphorumThe US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.Read full story pharminent May 19, 2026 (Last updated: May 19, 2026) Pharmaphorum The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare’s drug pricing negotiation powers. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: 225: An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics AcceleratorNext: Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates Related Stories Policy / Pricing German said to be backtracking on pharma rebate changes pharminent June 16, 2026 Policy / Pricing Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026 pharminent June 11, 2026 Policy / Pricing How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market pharminent June 11, 2026
